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When dietary choline is restricted, mostmen and postmeno-
pausal women developmultiorgan dysfunctionmarked by he-
patic steatosis (choline deficiency syndrome (CDS)). However, a
significant subset of premenopausal women is protected from
CDS. Because hepatic PEMT (phosphatidylethanolamine
N-methyltransferase) catalyzes de novo biosynthesis of choline
and this gene is under estrogenic control, we hypothesized that
there are SNPs in PEMT that disrupt the hormonal regulation of
PEMT and thereby put women at risk for CDS. In this study, we
performed transcript-specific gene expression analysis, which
revealed that estrogen regulates PEMT in an isoform-specific
fashion. Locus-wide SNP analysis identified a risk-associated hap-
lotype that was selectively associated with loss of hormonal acti-
vation. Chromatin immunoprecipitation, analyzed by locus-wide
microarray studies, comprehensively identified regions of estro-
gen receptor binding in PEMT. The polymorphism (rs12325817)
most highly linked with the development of CDS (p < 0.00006)
was located within 1 kb of the critical estrogen response element.
The risk allele failed to bind either the estrogen receptor or the
pioneer factor FOXA1. These data demonstrate that allele-spe-
cific ablation of estrogen receptor-DNA interaction in the PEMT
locus prevents hormone-inducible PEMT expression, conferring
risk of CDS in women.
In humans, dietary deficiency of choline results in liver and
muscle damage characterized by hepatosteatosis and elevated
serum levels of hepatic transaminases and creatine phos-
phokinase, subsequently referred to as choline deficiency-
induced syndrome (CDS)5 (1–4). Although CDS occurs in
most men and postmenopausal women deprived of dietary
choline, the majority (56%) of premenopausal women seem to
be protected against CDS (1).
The only de novo source of choline derives from hepatic
synthesis catalyzed by PEMT (phosphatidylethanolamine N-
methyltransferase) (5, 6). PEMT is regulated by estrogen in
human and mouse hepatocytes, but the mechanisms for this
regulation are unknown (7). Because endogenous choline pro-
duction could compensate for insufficient choline intake, we
suggest that many premenopausal women may be protected
from CDS by induction of PEMT by estrogen. This is impor-
tant because augmented production of choline may be partic-
ularly important during pregnancy and lactation, when de-
mand for choline is especially high due to transport of choline
from mother to fetus (8, 9). The National Academy of Sci-
ences set an adequate intake level for choline (10), but in the
United States, less than 15% of pregnant women eat the rec-
ommended amount (11). In fact, women vary enough in die-
tary choline intake (from 300 to 500 mg/day) to influence
the risk that they will have a baby with a birth defect; at least
25% of women eat so little choline that their pregnancies are
at risk (12–14). A 2009 study of 130,000 women in California
(14) reported elevated neural tube defect risk associated with
lower concentrations of choline in blood and reduced risk
with higher levels of choline. Specifically, they observed an
odds ratio of 2.4 (95% confidence interval  1.3–4.7) associ-
ated with the lowest decile and an odds ratio of 0.14 (0.02–
1.0) associated with the highest decile, both relative to the
25th to 74th percentiles of the control distribution (14).
Although most young women are resistant to CDS, more
than 40% of them do require a source of dietary choline, or
they develop fatty liver (1). We hypothesize that these women
are insensitive to estrogenic activation of PEMT because of a
functional polymorphism that alters the interaction of the
gene with estrogen. Therefore, these women are dependent
on dietary choline. This hypothesis is supported by existing
data; Pemt disruption predisposes to hepatic steatosis in mice
(15–17), and a functional polymorphism in PEMT (V175M)
was significantly associated with nonalcoholic hepatic steato-
sis in populations in the United States and Japan (18, 19). In-
deed, we identified a single nucleotide polymorphism (SNP)
in the promoter region of PEMT (rs12325817) that was asso-
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ciated with a greatly increased risk for developing organ dys-
function in premenopausal female carriers when fed a low
choline diet (20). The mechanism of action for the effect of
this SNP on risk for CDS has not been identified.
To further elucidate the mechanism for allelic differences
in PEMT regulation, we identified the CDS risk-associated
haploblock. Using allele- and transcript-specific gene expres-
sion analyses, we identified the PEMT transcripts that were
induced by estrogen and demonstrated that, in primary hu-
man hepatocytes, estrogen responsiveness was abrogated in
the risk haploblock. We comprehensively analyzed ER-chro-
matin interaction to identify the location of estrogen regula-
tory regions in the PEMT locus. We found that the risk hap-
loblock failed to bind the estrogen receptor or the cooperative
transcriptional regulator FOXA1 and was unable to mediate
hormonal transcriptional regulation.
Our results suggest that a risk haplotype located in the
PEMT gene directly abrogates estrogenic regulation of PEMT,
explaining how genetic variation influences gender-specific
dietary choline requirements, placing young women at risk of
CDS.
EXPERIMENTAL PROCEDURES
Cell Culture—Primary human liver cells were provided as a
gift by Admet Technologies (Durham, NC). These studies
were approved by the institutional review board of the Uni-
versity of North Carolina at Chapel Hill; informed consent
was not obtained because the data were analyzed anony-
mously. Hepatocytes were isolated as described previously (7).
Cells were plated at a density of 1.8  106 cells/9.6 cm2 on
collagen-coated culture plates (BD Biosciences) and incu-
bated for 6 h at 37 °C in humidified air containing 5% CO2 in
Williams’ complete medium E (Invitrogen) containing 10%
dextran-treated charcoal-stripped fetal bovine serum
(Biomeda, Foster City, CA) and antibiotics (100 units/ml pen-
icillin and 100 g/ml streptomycin; Sigma-Aldrich). Medium
was replaced at 6 h with serum-free Williams’ complete me-
dium E. All experimentation involving human cells was car-
ried out following a 48-h “recovery period” in serum-free Wil-
liams’ complete medium E.
ChIP-chip and ChIP-qPCR—Chromatin prepared from
formaldehyde-fixed primary hepatocytes after a 45-min incu-
bation with 100 nmol/liter 17--estradiol (E2) (Sigma-Al-
drich) was immunoprecipitated with anti-ER (Ab-10, Neo-
markers; HC-20, Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA)) or FoxA1 antibodies (Ab5089, Abcam (Cambridge,
MA)) prebound to Ultralink protein A/G beads (Pierce) for a
minimum of 6 h at 4 °C as described previously (21, 22). Im-
munoprecipitated chromatin as well as unfractionated input
control chromatin were fluorescently labeled and hybridized
to a custom designed array (Roche-Nimblegen, Madison, WI)
that tiled 430 kb of Chr 17 harboring the PEMT locus and
several other genomic locations corresponding to previously
identified ER binding sites (21, 23–25) with 60-nucleotide
overlapping isothermal probes after eliminating repetitive
regions. Chromatin was analyzed by microarray hybridization
as described previously (26). Peaks with an average enrich-
ment ratio (log2) 2 and width 150 bp that were indepen-
dently identified by Mpeak (27) were selected for further
study. Primers for quantitative PCR were designed using
Primer Express (Primer 3 (28)). Purified DNA was subjected
to PCR using the Applied Biosystems SYBR Green Master-
mix. Relative DNA quantities were measured using a Nano-
Drop UV spectrophotometer (Thermo Fisher Scientific, Wal-
tham, MA). Sequences of qPCR primers are available upon
request.
Transcript-specific Gene Expression—Primary human hepa-
tocytes cultured for 48 h in hormone-free medium in 6-well
collagen-coated plates (BD Biosciences) were treated with 100
nM moxesterol. RNA was isolated (RNeasy, Qiagen (Gaithers-
burg, MD)) and analyzed by quantitative PCR (Taqman, Ap-
plied Biosystems (Foster City, CA)) with probes specific for
each PEMT transcript (Transcript A, NM_148172, assay
ID Hs01002998_m1; Transcript B, NM_007169, assay ID
Hs00200354_m1; Transcript C, NM_148173, custom assay ID
4331348). To determine the absolute copy number of the tar-
get transcripts, we cloned a cDNA fragment unique to each
PEMT transcript isolated from human liver RNA into a
TOPOII TA (Invitrogen). The copy number of unknown sam-
ples (RNA extracted at various time points from human hepa-
tocytes) was determined by linear regression analysis utilizing
transcript-specific standard curves. To correct for differences
in both RNA quality and quantity between samples, the ex-
pression levels of transcripts of interest were normalized to
GAPDH and expressed as a ratio of gene expression change.
Transcripts in Human Liver—Human male liver biopsy
samples (Liver Tissue Procurement and Distribution System
(Minneapolis, MN); n  6) were snap-frozen in liquid nitro-
gen immediately following harvest. RNA was isolated (TRIzol,
Invitrogen) and analyzed by quantitative PCR (Taqman, Ap-
plied Biosystems) with probes specific for each PEMT tran-
script as described previously. To correct for differences in
both RNA quality and quantity between samples, the expres-
sion levels of transcripts of interest were normalized to
GAPDH and expressed as a ratio of gene expression change.
We also calculated results by normalizing to the amount of
cDNA; both calculations yielded similar results.
Identification of the Choline Deficiency Syndrome-associ-
ated Haplotype in the PEMT Locus—As part of a University of
North Carolina institutional review board-approved study, 57
human subjects were fed a defined diet containing 550 mg of
choline/70 kg of body weight/day for 10 days and then were
fed a defined low choline diet (50 mg of choline/70 kg of
body weight/day) either until the development of organ dys-
function or for a period of up to 42 days. The design of this
study has been described elsewhere (1, 20, 29). Organ dys-
function associated with choline deficiency was defined as a
greater than 5-fold increase of serum CPK activity; a 1.5-fold
increase in serum activity of aspartate transaminase, alanine
transaminase, -glutamyl transpeptidase, or lactic dehydro-
genase; or an increase in liver fat content of more than 28%
(assessed by magnetic resonance imaging) that was resolved
upon reintroduction of choline to the diet. DNA isolated from
women (n  64) and men (n  26) who participated in the
study was genotyped for a selection of SNPs in the PEMT lo-
cus by sequencing, using primers described previously
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(20) or by a Taqman SNP genotyping assay (catalog no.
C_9246129_10, Applied Biosystems).
Allele-specific Gene Expression—For allele imbalance exper-
iments, primary hepatocytes were genotyped for the exonic
(rs897453) and CDS-associated (rs4646343) SNPs by qPCR
using TaqMan primer-probe assays (Assays on Demand SNP
genotyping assay; Applied Biosystems): SNP rs897453
(assay ID C___7443062_1_); SNP rs4646343 (assay ID
C___9246129_10). To quantify expression differences be-
tween the risk and protective allele, a standard curve was gen-
erated by mixing genomic DNA from homozygous risk indi-
viduals (defined as rs4646343 (A/A) and homozygous
protective individuals (rs4646343 (C/C)) at five ratios fol-
lowed by qPCR with a TaqMan assay specific for each
rs897453 allele. cDNA was generated (SSIII First Strand syn-
thesis kit, Invitrogen) from hormone-treated and -untreated
hepatocytes heterozygous for SNPs rs897453 and rs4646343.
After allele-specific TaqMan, we deduced the ratios of gene
expression between the two alleles as described previously
(30). Allele-specific detection of PEMT in genomic DNA (pre-
dicted to be 50%) served to normalize cDNA ratios. Results
are presented as a percentage of risk allele expression.
Transcript-specific allele imbalance experiments were
performed with primer-probe sets unique for each tran-
script (as described above) in hepatocytes homozygous for
the risk allele (R) (n  5), homozygous for the protective
allele (P) (n  6), and heterozygous for the protective/risk
alleles (P/R) (n  5).
Haplotype-specific Estrogen-induced Changes in PEMT En-
zyme Activity—Primary human hepatocytes were obtained
fresh from CellzDirect (Durham, NC) and cryopreserved from
Zen-Bio (RTP). They were genotyped for rs12325817 and
rs4646343 as described previously. Cells were plated at a den-
sity of 1  106 cells/well on collagen-coated 6-well culture
plates (BD Biosciences) and incubated for 6 h at 37 °C in hu-
midified air containing 5% CO2 in Hepatocyte Plating Me-
dium (HM-1, Zen-Bio). Medium was replaced at 6 h with se-
rum-free phenol red-free Hepatocyte Maintenance Medium
(HM-2, Zen-Bio) for 15 h to recover. The primary cells were
then incubated for 24 h in HM-2 with 0 or 100 nmol/liter
moxestrol (Steraloids, Newport, RI). Cells were washed twice
with 1 PBS, scraped into medium A (250 mmol/liter su-
crose, 100 mmol/liter Tris, 0.1 mmol/liter EGTA, and 5
mmol/liter dithiothreitol, pH 8) and homogenized. Homoge-
nate containing 50 g of protein was used for PEMT activity
assays as described previously using phosphatidyldimethyl-
ethanolamine (Avanti Polar Lipids, Alabaster, AL) as the
methyl acceptor and S-adenosyl-L-[methyl-3H]methionine
(American Radiolabeled Chemicals Inc., St. Louis, MO) as the
methyl group donor (6). C57BL/6 mouse primary hepatocytes
were used as a positive control in these experiments.
Construction of Plasmids and Luciferase Reporter Assay—
Genomic DNA was extracted from human hepatocytes and
used to amplify a segment of the 5-flanking region of the
transcription start site for PEMT transcript B (NM_007169).
The 1.3-kb PCR product was directionally subcloned (BglII/
HindIII) into the promoterless expression vector, pGL4-Basic
(Promega, Madison, WI), Plasmid was designated as pGL4-
PEMT B (supplemental Table 1). ER binding sites identified
by ChIP (peaks II–IV, III/IV, and IV) were amplified from
human liver genomic DNA by PCR and subcloned (KpnI/
Xho; Xho/Xho) into the pGL4-SV40 vector (Promega; Madi-
son, Wisconsin) and pGL4-PEMT B. Site-directed mutagene-
sis (Stratagene, La Jolla, CA) of the peak IV pGL4-SV40
construct was performed using a QuikChange XL site-di-
rected mutagenesis kit (Stratagene) according to the manu-
facturer’s protocol. Clones were verified by sequencing (Uni-
versity of North Carolina Genome Analysis Facility). MCF7
cells cultured for 24 h in phenol red-free DMEM with 1%
charcoal/dextran-treated FBS (Hyclone) were transfected
with ER pGL4-PEMT B and pGL4-SV40 constructs
(FuGENE HD transfection reagent, Roche Applied Science).
Twenty-four hours after transfection, cells were treated with
100 nmol/liter moxestrol.
Human primary hepatocytes grown in serum-free/hor-
mone-depleted medium for at least 2 days in 24-well collagen-
coated plates (BD Biosciences) were transfected with JETPEI
hepatocyte transfection reagent (Genesee Scientific, San Di-
ego, CA). Twenty-four hours after transfection, cells were
treated with 100 mmol/liter moxestrol. Cell lysates were as-
sessed using the Dual Luciferase Reporter Assay system
(Promega).
Statistical Analysis—For the luciferase reporter assay and
the allele-specific gene expression studies, statistical differ-
ences in treatment were determined using Student’s t test
(31). For the choline depletion study, a Fisher’s exact test was
used to determine statistical significance of SNP association
with organ dysfunction (31). For chromatin studies, a mixed
model was applied with signal ratio (immunoprecipitated
chromatin/input control) as the response, treatment group
(estrogen-treated and -untreated) and genotype (P, P/R, and
R) as fixed effects, and genomic region (peaks II, III, IV, and V
and negative control) as a random effect (31). For qPCR, a
repeated measures model was applied with the gene expres-
sion ratio (ln(PEMT/GAPDH)) as the response and treatment
group (moxestrol-treated and -untreated), time (4, 8, and
24 h), and genotype as predictors (31). (Analysis was rerun for
each transcript.) Terms testing for interactions between the
fixed effects predictors were included. Interaction terms with
a p value greater than 0.10 were removed, and the models
were repeated. An unstructured correlation matrix to account
for the correlation of the observations within each subject at
each time/region was included in the model (31). For the
transcript-specific gene expression analysis in human liver
biopsies and the PEMT activity studies, statistical differences
were assessed using an analysis of variance and Tukey-
Kramer test.
RESULTS
Identification of a CDS-associated Haploblock—We had
previously performed a clinical study that assessed human
dietary choline requirements (1). In that study, we examined a
targeted set of SNPs in genes involved in choline metabolism
(five SNPs, including two in PEMT) and identified one SNP in
PEMT (rs12325817) that was highly associated with CDS in
women (20). We now completed an analysis of an additional
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33 women subjected to the same clinical protocol (bringing
the total to 64 women) and confirmed the association be-
tween risk of CDS and the presence of at least one variant
allele marked by rs12325817 (p  9  106). In addition, we
examined another SNP in PEMT (rs4646343; located within
intron IA) in these 64 women and found that rs4646343
(present in the HapMap data base (32, 33)) was highly associ-
ated with risk for CDS (p  6.2  105). Ninety-two percent
of the 64 women with a variant allele for rs12325817 also had
a variant allele for rs4646343.
Estrogen Regulation of PEMT Is Transcript-specific—To
begin to understand the mechanism for estrogenic control of
PEMT, we examined the regulation of the three PEMT tran-
scripts. Each transcript is regulated by a distinct promoter
and contains a unique first exon (Fig. 1). Using transcript-
specific primer-probe sets and cDNA standards, we quanti-
fied the absolute level of expression of each transcript with
and without treatment with the estrogen analog moxestrol.
This synthetic estrogen was used because it is not subject to
cytochrome P450 metabolism expected in primary hepato-
cytes (34, 35). Although transcript A was most abundant in
unstimulated cells (7.5  105 copies/150 ng of cDNA), it
was not induced at any time point tested (Fig. 2, A and D). In
contrast, transcripts B and C were significantly induced (Fig.
2, B–D). Upon moxestrol treatment, transcript B became the
predominant transcript, exceeding levels of transcript A at
8 h. Transcript C was the least abundant. These data suggest
that estrogen selectively activates transcripts B and C.
PEMT A is the major transcript in human liver. In six male
human liver biopsy samples, PEMT transcript A mRNA was
6 times more abundant than was transcript B and transcript
C mRNA (p  0.01; Fig. 2E).
Risk Allele Is Not Estrogen-responsive—Using HapMap data,
other PEMT SNPs were found to be in high linkage disequi-
librium with rs4646343, including an SNP located in common
exon 3 (rs897453) (Centre d’Etude du Polymorphisme Hu-
main (CEPH); r2  0.67) (Fig. 1) (note that rs12325817 was
not assessed in the HapMap study) (25, 26). This non-synony-
mous SNP encodes a conservative amino acid substitution
(Val3 Ile). The availability of a common exonic SNP in link-
age disequilibrium with the CDS risk-associated SNP enabled
examination of allele-specific expression.
Human liver organ donors were genotyped to determine
their SNP status at the CDS-associated allele, rs4646343, and
the exonic allele, rs897453. We quantified the relative expres-
sion of PEMT from the risk and the non-risk alleles in het-
erozygous hepatocytes by leveraging the association with the
exonic SNP with and without moxestrol treatment. In un-
treated hepatocytes, the risk allele was underexpressed by
4% relative to the protective allele (p  0.01), and after
treatment with moxestrol, the risk allele was underexpressed
by 8% (p  0.0002; Fig. 3A).
To explore whether expression of the protective allele may
compensate for the underexpression of the risk allele, we
compared PEMT transcript levels in human hepatocytes after
treatment with moxestrol. In contrast to PEMT transcript A,
for which genotype was not associated with differences in
expression (p  0.06), transcripts B and C demonstrated a
highly significant interaction between response to treatment
and genotype (p  0.0001 for both). Transcripts B and C were
induced less in cells homozygous for the risk allele than in
cells heterozygous for the risk allele or homozygous for the
protective allele (Fig. 3B).There is also a trend toward de-
creased basal expression of transcripts A and B in the pres-
ence of the risk allele. These allele-specific data further sup-
port the association of CDS-linked SNPs with the absence of
hormonal PEMT regulation.
Identification of ER Binding Sites in the PEMT Locus in Hu-
man Hepatocytes—To identify the mechanism for estrogenic
activation of the B and C transcripts, we comprehensively
identified sites of ER interaction with the PEMT locus. Chro-
matin was isolated from primary human hepatocytes before
and after treatment with estradiol and immunoprecipitated
(ChIP) with estrogen receptor  antibodies (ER, the major
isoform in liver (36)). Immunoprecipitated and total (input
control) chromatin were hybridized to a microarray that tiled
virtually the entire PEMT locus with densely spaced, overlap-
ping probes (Fig. 4A). Because previous genome-wide studies
FIGURE 1. PEMT SNPs are associated with CDS risk in women. Shown is a schematic representation of the PEMT locus, including alternative transcrip-
tional start sites (A, B, and C), and location of SNPs (rs12325817 and rs4646343) highly linked to the CDS phenotype in humans fed a low choline diet. Using
HapMap data, other SNPs in this region were found to be in high linkage disequilibrium with rs4646343, including an SNP located in common exon 3
(rs897453) (Centre d’Etude du Polymorphisme Humain (CEPH); r2  0.695).
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had identified functional ER binding sites several hundred kb
from regulated genes (21), we designed our arrays to include
430 kb surrounding the PEMT gene. As positive controls, we
also tiled genomic loci previously shown to bind ER in other
cell types. We found that 56% of these regions exhibited ER
binding in our experiments (data not shown).
Using the positive control regions to establish peak detec-
tion parameters, seven putative ER binding sites were identi-
fied in the PEMT gene using chromatin from primary human
hepatocytes harboring the protective haplotype (Fig. 4B). Rep-
licate data from a second independent experiment demon-
strated identical binding at six of seven sites (data not shown).
These seven putative ER binding sites, comprising three clus-
ters, were located between the PEMT A transcriptional start
site (TSS) and the shared second intron 3 to the PEMT C
TSS. The major cluster (cluster 1) consisted of four separate
regions located 6.9 kb 5 from the TSS for PEMT B.
To quantify differential ER binding to these regions, ChIP-
qPCR was performed on chromatin isolated from primary
human hepatocytes before and after treatment with estradiol.
Each of the regions within intron 1A was examined sepa-
rately. Compared with untreated chromatin, estrogen signifi-
cantly increased binding to regions II, III, IV, and V (p  0.05)
(Fig. 4C) but did not induce binding when probed with a non-
specific antibody (IgE) (supplemental Fig. 3). Sites I, VI, and
VII did not exhibit estrogen-induced binding, similar to a
negative control site in the region. Region IV contains a con-
sensus estrogen response element (ERE; GTCA-xxx-TGACC)
FIGURE 2. Estrogen regulation of PEMT is transcript-specific. Using RNA isolated from primary hepatocytes cultured in the absence () or presence ()
of 100 nmol/liter moxestrol for the lengths of time noted, PEMT transcripts were quantified using transcript-specific primers by quantitative PCR. A, tran-
script A, initially the most abundant, was not responsive to hormone treatment. B, transcript B was significantly induced in response to hormone treatment
at both 8 and 24 h after treatment. C, transcript C was the least abundant but was significantly induced in response to hormone treatment at 8 and 24 h.
D, PEMT expression levels, presented as a ratio of treated/untreated for all transcripts (normalized to GAPDH), demonstrated significant induction of B (all
time points tested) and transcript C (at the 8 and 24 h time points). E, RNA isolated from male human liver biopsies and primary human hepatocytes was
subjected to transcript-specific quantitative PCR. For human biopsy samples, results are presented as an average for all subjects (n  6), and for human
hepatocytes, results are shown as an average of all untreated samples, across all time points. Transcripts A and B were significantly more abundant than
transcript C. Transcript A was significantly more abundant than transcript B (n  5– 6/time point; *, p  0.05; **, p  0.01). Error bars, S.E.
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as well as a FOXA1 site, both of which are evolutionarily con-
served between humans and mice. Although the PEMT locus
contains 29 predicted imperfect ERE motifs (TRANSFAC
(37)), none of these sites demonstrated enrichment.
To examine whether sites of ER binding can act as hor-
mone-responsive transcriptional enhancers in human hepato-
cytes, the intron IA (containing peaks II–IV) and promoter B
(peak V) genomic regions were isolated from human hepato-
cytes harboring the protective haplotype and cloned upstream
of an SV40 minimal promoter (Fig. 4D). Because site IV con-
tains the consensus ERE, this region was also cloned sepa-
rately from sites I–III. These constructs were transiently
transfected into hormone-depleted primary human hepato-
cytes. The region containing sites II–IV was capable of medi-
ating estrogenic activation (Fig. 4D). When separated, site IV
but not sites II/III mediated hormonal activation. Although
site V binds ER and induces basal transcription (data not
shown), it failed to confer estrogen responsiveness. As further
confirmation, these regions were placed upstream of the
PEMT B proximal promoter and assayed in MCF7 or liver-
derived HepG2 cells. The peaks II–IV and peak IV alone were
again able to function as an estrogen-responsive enhancer
(p  0.01; supplemental Figs. 1 and 2). The estrogen receptor
is necessary for hormone activity (supplemental Fig. 2).
ER Fails to Bind the CDS Risk Allele—To determine if SNP
status affected ER binding to the PEMT locus, we performed
microarray-based analysis of chromatin isolated from estro-
gen-treated hepatocytes homozygous for the risk allele and
homozygous for the protective allele. Decreased estrogen
binding was evident at sites II, III, and IV in hepatocytes ho-
mozygous for the risk allele (Fig. 5A). ER binding to several
non-PEMT control sites was unaffected by genotype (Fig. 5B).
We validated the influence of SNP status on ER binding to
the PEMT locus by quantitatively analyzing ER-associated
chromatin isolated from R, P, and P/R primary hepatocytes.
Chromatin from hepatocytes heterozygous and homozygous
for the protective allele exhibited significant differences in ER
binding between treated and untreated hepatocytes for sites
II–IV (p  0.0001; Fig. 5C). Chromatin isolated from hepato-
cytes homozygous for the protective allele exhibited signifi-
cantly greater ER binding compared with chromatin isolated
from homozygous risk hepatocytes for regions III and IV (p 
0.05). In contrast, estrogen treatment failed to induce ER
binding in chromatin isolated from subjects homozygous for
FIGURE 3. PEMT risk allele is not estrogen-responsive. A, RNA isolated from primary hepatocytes heterozygous for the risk allele was subjected to allele-
specific quantitative PCR. Results were normalized to genomic DNA (black bars). The estimated relative expression of the risk allele cDNA versus the protec-
tive allele cDNA was calculated by linear regression analysis. In the absence of 100 nmol/liter moxestrol treatment (, open bars), the risk allele was under-
expressed by 4% relative to the protective allele. Upon moxesterol treatment (24 h) (, gray bars), the risk allele was underexpressed by 8%. Based on
the transcript-specific expression data, the estimated relative abundance of unregulated transcript A in treated cells is depicted by the dashed line. Results
are presented for individual subjects and as an average for all subjects (n  9). *, p  0.01; **, p  0.001. Error bars, S.E. B, RNA was isolated from moxestrol-
treated (open diamonds) or untreated hepatocytes (black squares) that were P, R, or P/R. PEMT levels were determined by qPCR. Transcript A was not in-
duced by estrogen in any of the groups. Transcripts B and C were induced by hormone in the P and P/R groups, but in hepatocytes homozygous for the risk
allele (R), these transcripts were not induced by hormone treatment. Results are presented as the natural log (LN) of the ratio of PEMT relative to GAPDH
gene expression levels in moxestrol-treated versus untreated hepatocytes. (n  5– 6/genotype). *, p  0.001; **, p  0.0001. Error bars, S.E.
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the risk allele at all sites tested (I–V) (p  0.12). Because
FOXA1 has been shown to act to create a favorable chromatin
environment for ER binding, we then examined FOXA1 occu-
pancy at the site 52 bp from the ERE (Fig. 5D). As with ER,
FOXA1 chromatin interaction was also greatly influenced by
haplotype. Chromatin isolated from hepatocytes homozygous
for the protective allele exhibited significantly greater FOXA1
binding compared with chromatin isolated from homozygous
risk and heterozygous hepatocytes at region IV (p  0.05).
Hepatocytes with the CDS risk allele have decreased PEMT
activity. To determine whether the observed decrease in
PEMT gene expression resulted in a reduction in functional
PEMT enzyme levels, activity was measured in human hepa-
tocytes that were R, P, or P/R after treatment with moxestrol.
Untreated fresh hepatocytes had similar activity (16 	 7
pmol/h/mg protein) as those kept in culture for 48 h (14 	 4
pmol/h/mg protein; p  0.67). Hepatocytes homozygous for
the protective allele (P) had 2 	 0.1-fold more activity after
moxestrol than did untreated cells, whereas hepatocytes with
the risk allele (P/R and R) had 1.3 	 0.1-fold more activity
after moxestrol than did untreated cells (p  0.0018) (Fig. 6).
Only two samples of hepatocytes homozygous harboring the
risk allele could be obtained. In both samples, PEMT activity
did not increase after moxestrol (estrogen) treatment (Fig.
6). In comparison, hepatocytes from C57BL/6 mice had
2.7 	 0.1 times more PEMT activity after moxestrol treat-
ment (p  0.01).
DISCUSSION
For mammals, choline is an essential nutrient. Restricted
consumption leads to significant organ dysfunction (1, 20)
and increases the risk of giving birth to a baby with a neural
tube and/or orofacial defect (12, 13). De novo choline produc-
tion through PEMT-catalyzed conversion of phosphatidyleth-
anolamine to phosphatidylcholine can compensate for re-
duced dietary choline intake (38). In a clinical study, we had
identified a subset of young women who were protected
against CDS (relative to men and postmenopausal women)
(1), and we suggested that this protection resulted from an
enhanced capacity for de novo choline production by estro-
gen-mediated induction of PEMT (7).
In this study, we more fully identified the haploblock asso-
ciated with protection from CDS and determined the mecha-
nism for hormonal regulation of PEMT. Using a targeted
(rather than a genome-wide) SNP association study, we iden-
tified two PEMT SNPs in linkage disequilibrium that charac-
terized a haplotype associated with greatly increased risk of
CDS in women (rs12325817, p  0.000009; rs4646343, p 
0.000062). Based on the genotype determined by these SNPs,
we demonstrated allele- and transcript-specific differences in
hormonal responsiveness in primary human hepatocytes. Us-
ing locus-wide chromatin immunoprecipitation studies, we
identified regions of estrogen receptor contact with DNA that
could induce gene expression. Finally, we showed that the risk
haplotype was associated with decreased ER binding com-
pared with the same region containing the protective haplo-
type. ER interaction at all sites was abrogated on the risk al-
lele. Specifically, we found that, in hepatocytes homozygous
FIGURE 4. Identification of ER binding sites within PEMT. The PEMT gene
encodes three isoforms that are distinguished by unique leading exons, IA,
IB, and IC. The dotted lines indicate splicing of exons IA–IC to common ex-
ons II–VII. Chromatin isolated from human hepatocytes incubated for 45
min with 100 nmol/liter estradiol (E2) was immunoprecipitated with anti-
ER antibody and hybridized, together with unfractionated chromatin, to a
microarray that densely tiled virtually the entire PEMT locus. A, schematic
depiction of the PEMT locus. Locus-wide chromatin immunoprecipitation
data are expressed as the ratio of immunoprecipitated chromatin to input
control (IP/IC). Only positive enrichment ratios of ChIP signal to input con-
trol signal are shown. B, seven ER binding regions were mapped within
three clusters in close proximity to transcription start sites A, B, and C. The
boxed regions indicate identified peaks. C, quantitative PCR was performed
on chromatin from cells before and after 45-min exposure to 100 nmol/liter
E2 treatment with primers specific to the seven microarray-defined regions
(as well as a negative control (neg ctrl)). ER binding to peaks within intron IA
and 3 to the B TSS was significantly increased by E2 (n  3). *, p  0.05.
D, ER binding regions (peaks II–IV and peak V) from the protective haplo-
type were cloned upstream of the SV40 promoter and transfected into pri-
mary human hepatocytes grown in hormone-depleted media. Cells were
either untreated or treated with 100 nmol/liter moxestrol (MOX). Peak IV
(indicated by the red arrow) harbors the consensus ERE. The green box rep-
resents the SV40 promoter, which drives expression of the luciferase gene.
The data represent the average relative luciferase activity normalized for
Renilla luciferase and are expressed as -fold induction relative to the activity
in the absence of moxestrol. Absolute values for both treated () and un-
treated () cells are presented separately in the table. *, p  0.05 compared
with untreated.
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FIGURE 5. Choline deficiency syndrome-associated risk allele fails to bind ER. A, chromatin isolated from 100 nmol/liter estradiol-treated hepatocytes homozy-
gous for the protective or risk alleles was immunoprecipitated with anti-ER antibodies and hybridized to densely tiled oligonucleotide microarrays. Estrogen re-
ceptor complex (ER) binding was decreased for the risk haplotype at peaks II–IV. Chromatin from estradiol-treated () or untreated () hepatocytes homozygous
(P and R) or heterozygous (P/R) for the protective or risk alleles was immunoprecipitated with anti-ER (B) and anti-FOXA1 (C) antibodies followed by amplification
with primers specific for ER-associated regions. Whereas ER binding to peaks II–IV was significantly induced by estrogen for the protective allele, estrogen failed to
significantly augment ER binding to the risk allele (n  5–6/genotype). *, p  0.0001. Data are expressed as the ratio of immunoprecipitated chromatin to input
control (IP/IC). Error bars, S.E. D, ER binding to representative sites on control genes (PGR, ESR1, and MYC) was unaffected by haplotype.
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for the risk allele, ER binding to the region containing the ERE
was not induced by estrogen. Interestingly, ER binding at peak
V (6800 bp from peak IV) also was diminished in the con-
text of the risk allele, suggesting that proximal promoter sites
of ER interaction are coordinately disrupted by the risk-asso-
ciated SNPs.
PEMT generates three transcripts (PEMT A, B, and C). Al-
though transcript A constitutes nearly half of the total PEMT
message in estrogen-treated hepatocytes, the development of
CDS was associated with diminished PEMT B and C. In het-
erozygous cells, allele-specific transcript detection demon-
strated greatly diminished estrogen-induced expression from
the CDS risk allele in the absence of allelic compensation.
Because the technique to determine allele-specific expression
could not discriminate between transcript isoforms, it is likely
that the abundance of transcript A (unaffected allele) masks a
significantly greater reduction in transcript B and C expres-
sion (affected allele). These data highlight the importance of
accounting for transcript isoforms when examining allelic
imbalance and could explain the findings of a recent genome-
wide association study in human liver, which failed to identify
significant allelic expression imbalance associated with PEMT
SNP rs897453 (27). In addition, these data suggest that either
the degree of PEMT B induction is physiologically relevant or
the PEMT B isoform may be acting in a fashion distinct from
PEMT A. Total PEMT activity was induced in the presence of
moxestrol in hepatocytes homozygous for the protective allele
and was abrogated by the risk allele.
To understand why estrogen failed to activate the risk al-
lele, we performed detailed, locus-wide chromatin immuno-
precipitation. We identified several putative ER binding sites
in the PEMT gene, including a cluster of sites 6.8 kb up-
stream of the TSS of the B transcript (in the first intron of the
PEMT A isoform). Previous efforts to map ER binding ge-
nome-wide had not detected these sites (21, 24, 36). This dif-
ference may reflect the tissue- and/or species-specific nature
of this interaction.
We resolved ER binding cluster I (Fig. 4B) into three dis-
tinct binding sites (annotated as peaks I–IV). Peak IV medi-
ated estrogen responsiveness in a co-transfection assay. Peak
IV contains a canonical ERE motif and a FOXA1 site. In addi-
tion to the peak IV canonical ERE region, other sites of ER
chromatin contact were identified. In isolation, these were
unable to mediate estrogen-responsive transcription, al-
though several of these non-ERE-containing sites confer non-
hormone-responsive cis-regulatory activity indicative of a
functional enhancer element. These data suggest multiple
contact sites for a protein complex that includes ER. Despite
the proximity of the ERE to the transcriptional start site of the
A transcript, this transcript was not regulated by estrogen.
Direct sequencing of the risk and protective alleles failed to
demonstrate alterations of the ERE or FOXA1 recognition
sites. Neither the SNP linked to CDS in our original study
(rs12325817) nor the SNP identified in this study (rs4646343)
resides in an ER binding region. Although it is possible that
these SNPs mediate the difference in chromatin structure,
there are several other SNPs in the region. Differences in in-
heritance and the relatively small number of subjects in our
clinical study make it difficult to confidently narrow down
possibilities among these potentially critical SNPs.
FOXA1, also known as HNF3 (hepatocyte nuclear factor
3), together with FOXA2, is critical for liver development in
mice (39). FOXA1 functions to open chromatin, increasing
the accessibility of other transcription factors (40). Specifi-
cally, FOXA1 was recently shown to be critical in determining
sites of estrogen receptor activity (41). This cooperative na-
ture of FOXA1 and ER suggests that without FOXA1 binding
to PEMT, there may be a loss of ER binding and hormonal
regulation of PEMT expression. It is possible that polymor-
phisms in the risk allele alter the binding of FOXA1 directly
or through the recruitment of other chromatin modifiers that
could indirectly influence FOXA1 chromatin association.
Based on the results of our study, we predict that women
harboring risk-associated SNPs abrogating hormonal regula-
tion of PEMT will have a higher dietary requirement for cho-
line because they cannot augment endogenous production of
choline with estrogen. This haplotype could identify young
women at risk for liver and muscle damage as well as for ab-
normal pregnancy outcomes when dietary choline is limited.
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